Jerry Radich, Fred Hutchinson Cancer Research Center, Seattle, USA
Please wait some seconds before the educational presentation will start below. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and see the other Virtual Education Program modules.
Issues covered
The role of transplantation in 2011
Who should be transplanted
When they should be transplanted
Why they should be transplanted
Has this been helpful? Please provide your comments here:
Facteur de variabilité de la réponse au ITK</li> <li>Les trois grand mécanismes de résistance</li> <li>La réponse au traitement</li> <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib